Research and Markets: Global Acute Coronary Syndrome Epidemiology and Patient Flow Analysis 2015

<0> Research and Markets: Global Acute Coronary Syndrome Epidemiology and Patient Flow Analysis 2015 </0>

<0> Research and MarketsLaura Wood, Senior ManagerFor EST Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

The report provides insights into Acute Coronary Syndrome epidemiology, Acute Coronary Syndrome diagnosed patients, and Acute Coronary Syndrome treatment rate for the top seven pharmaceutical markets. The study measures key indicators such as prevalence of Acute Coronary Syndrome derived from epidemiological analysis, percentage of patients diagnosed with Acute Coronary Syndrome, and percentage of patients treated with Acute Coronary Syndrome therapy.

The study helps executives estimate Acute Coronary Syndrome market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Acute Coronary Syndrome prevalence, Acute Coronary Syndrome diagnosis rate, and Acute Coronary Syndrome treatment rate for the period 2014 - 2020. The information is presented by leading geographies, including the US, Germany, France, Spain, Italy, UK, and Japan.

1. Acute Coronary Syndrome: Disease Definition

2. Global Acute Coronary Syndrome Patient Flow

3. Acute Coronary Syndrome Patient Flow in the US

4. Acute Coronary Syndrome Patient Flow in Europe

5. Acute Coronary Syndrome Patient Flow in Germany

6. Acute Coronary Syndrome Patient Flow in France

7. Acute Coronary Syndrome Patient Flow in Spain

8. Acute Coronary Syndrome Patient Flow in Italy

9. Acute Coronary Syndrome Patient Flow in UK

10. Acute Coronary Syndrome Patient Flow in Japan

11. Appendix

For more information visit .

Suggested Articles

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.

Pfizer CEO Albert Bourla clarified that collecting safety data means a submission or FDA authorization won't happen until late November.